Gan & Lee Pharmaceuticals Unveils New Diabetes Treatments at ADA 85th Scientific Sessions
Gan & Lee Pharmaceuticals Unveils New Diabetes Treatments at ADA 85th Scientific Sessions
Gan & Lee Pharmaceuticals has recently presented promising results regarding its innovative diabetes treatments at the American Diabetes Association’s 85th Scientific Sessions. The leading pharmaceutical company showcased findings from various Phase 2 clinical trials, emphasizing the effectiveness of their ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) injection, known as bofanglutide (GZR18), as well as a once-weekly basal insulin analog injection, GZR4.
Overview of the Trials
Bofanglutide Injection
In a Phase 2a clinical trial involving 36 adults with type 2 diabetes mellitus (T2DM), the bofanglutide injection was administered weekly for 23 weeks. This trial demonstrated a significant reduction in HbA1c levels. On average, participants experienced a decrease of 1.81% in HbA1c from baseline, while those in the placebo group showed minimal change. Furthermore, 57.7% of participants reached an HbA1c target of less than 7.0%, indicating the drug's potential in managing diabetes effectively.
Additionally, participants using bofanglutide reported a mean body weight reduction of 6.92 kg, showcasing its additional benefits in weight management, blood pressure control, and improved lipid profiles. Safety evaluations revealed that the injection was well tolerated, with the most reported side effects being mild-to-moderate gastrointestinal issues.
Phase 2b Study Comparison
The trial design advanced with a Phase 2b study, comparing bofanglutide against semaglutide (Ozempic®), enrolling 272 T2DM patients. Results revealed that bofanglutide outperformed semaglutide in terms of reductions in HbA1c and body weight. At doses of 18 mg every two weeks and 24 mg weekly, patients achieved mean reductions in HbA1c of 2.28% and 2.32%, respectively, which were statistically significantly superior to the 1.60% reduction observed in the semaglutide group. These findings highlight bofanglutide's potential as a leading treatment option as patients often struggle to adequately control their diabetes with existing medications.
GZR4 Injection
Meanwhile, GZR4's performance was evaluated in a separate Phase 2 clinical trial focusing on patients whose T2DM was inadequately controlled while on oral medications and those on prior basal insulin therapy. The findings showed comparable HbA1c efficacy between GZR4 and daily insulin degludec (Tresiba®) in newly diagnosed patients. In contrast, patients receiving GZR4 demonstrated superior HbA1c reduction compared to those using daily insulin in the latter segment of the study, achieving greater numbers of patients meeting HbA1c targets of less than 7.0% and less than 6.5%.
Exciting Future for Diabetes Treatment
The results presented at the ADA conference position Gan & Lee Pharmaceuticals as a front-runner in developing long-acting antidiabetic therapies. Following these compelling results, the company is accelerating Phase 3 clinical programs in China for both bofanglutide and GZR4 injections.
Gan & Lee Pharmaceuticals is committed to providing innovative solutions for diabetes management and aims to offer better treatment options to patients worldwide. With ongoing research and development efforts, the company’s mission extends beyond diabetes, promising to explore new entities and supplies targeting various therapeutic areas, including metabolic and cardiovascular diseases.
Conclusion
Gan & Lee's presentation at the ADA 85th Scientific Sessions signifies a substantial step forward in diabetes treatments, not only through promising clinical trial findings but also through the commitment to enhancing patient care globally. The company’s dedication to research signifies the potential for transformative diabetes therapies on the horizon.
For further updates on Gan & Lee Pharmaceuticals, stakeholders and interested parties are encouraged to stay tuned as the company releases additional data and insights on these promising new therapies.